CLU and prostate cancer: In prostate cancer cells, treatment with epigenetic drugs enhances histone H3 lysine 4 trimethylation (H3K4me3), decreases histone H3 lysine 27 trimethylation (H3K27me3), and induces CLU1 and CLU2 transcription.